Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""MUTATIONS"" wg kryterium: Temat


Tytuł :
Predicting Synthetic Lethality in Human Cancers via Multi-Graph Ensemble Neural Network.
Autorzy :
Lai M
Chen G
Yang H
Yang J
Jiang Z
Wu M
Zheng J
Pokaż więcej
Źródło :
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference [Annu Int Conf IEEE Eng Med Biol Soc] 2021 Nov; Vol. 2021, pp. 1731-1734.
Typ publikacji :
Journal Article
MeSH Terms :
Neoplasms*/genetics
Synthetic Lethal Mutations*/genetics
Artificial Intelligence ; Humans ; Neural Networks, Computer
Czasopismo naukowe
Tytuł :
Genetic landscape of T cells identifies synthetic lethality for T-ALL.
Autorzy :
O'Meara CP; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.
Guerri L; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.; Laboratory of Neurogenetics, National Institute of Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), Bethesda, MD, USA.
Lawir DF; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.; Institute of Zoology, Developmental Biology Unit, University of Cologne, Cologne, Germany.
Mateos F; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.
Iconomou M; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.
Iwanami N; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.; Center for Bioscience Research and Education, Utsunomiya University, Utsunomiya, Japan.
Soza-Ried C; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.; Fundacion Oncoloop & Center for Nuclear Medicine, Santiago, Chile.
Sikora K; Bioinformatics Unit, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.
Siamishi I; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.
Giorgetti O; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.
Peter S; Bioinformatics Unit, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Schorpp M; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany.
Boehm T; Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany. .; Faculty of Medicine, University of Freiburg, Freiburg, Germany. .
Pokaż więcej
Źródło :
Communications biology [Commun Biol] 2021 Oct 20; Vol. 4 (1), pp. 1201. Date of Electronic Publication: 2021 Oct 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Regulatory Networks*
Synthetic Lethal Mutations*
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*genetics
T-Lymphocytes/*metabolism
Animals ; Disease Models, Animal ; Epistasis, Genetic ; Phenotype ; Zebrafish
Czasopismo naukowe
Tytuł :
Synthetic lethality theory approaches to effective substance discovery and functional mechanisms elucidation of anti-cancer phytomedicine.
Autorzy :
Shan Y; Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Wang F; College of Food Science and Engineering/Collaborative Innovation Center for Modern Grain Circulation and Safety/Key Laboratory of Grains and Oils Quality Control and Processing, Nanjing University of Finance and Economics, Nanjing 210023, China.
Wei Z; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China. Electronic address: .
Lu Y; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China. Electronic address: .
Pokaż więcej
Źródło :
Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2021 Oct; Vol. 91, pp. 153718. Date of Electronic Publication: 2021 Aug 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drugs, Chinese Herbal*/pharmacology
Phytochemicals*/pharmacology
Synthetic Lethal Mutations*
Medicine, Chinese Traditional
Czasopismo naukowe
Tytuł :
Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers.
Autorzy :
Yao K; Brain Science Basic Laboratory, The Affiliated Wuxi Mental Health Center with Nanjing Medical University, Wuxi, 214151, Jiangsu, China.; Department of Clinical Psychology, The Affiliated Wuxi Mental Health Center with Nanjing Medical University, Wuxi, 214151, Jiangsu, China.
Liu H; Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, Jiangsu, China.
Yin J; Brain Science Basic Laboratory, The Affiliated Wuxi Mental Health Center with Nanjing Medical University, Wuxi, 214151, Jiangsu, China.
Yuan J; Brain Science Basic Laboratory, The Affiliated Wuxi Mental Health Center with Nanjing Medical University, Wuxi, 214151, Jiangsu, China. .
Tao H; Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, Jiangsu, China. .
Pokaż więcej
Źródło :
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2021 Aug 23; Vol. 40 (1), pp. 263. Date of Electronic Publication: 2021 Aug 23.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Synthetic Lethal Mutations*
Isocitrate Dehydrogenase/*genetics
Neoplasms/*genetics
Animals ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor ; Combined Modality Therapy/methods ; Drug Resistance, Neoplasm/genetics ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/pharmacology ; Enzyme Inhibitors/therapeutic use ; Gene Expression Regulation, Enzymologic ; Gene Expression Regulation, Neoplastic ; Humans ; Mitochondria/genetics ; Mitochondria/metabolism ; Molecular Targeted Therapy ; Neoplasms/metabolism ; Neoplasms/pathology ; Neoplasms/therapy ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Targeting "undruggable" c-Myc protein by synthetic lethality.
Autorzy :
Wang C; Division of Genome Medicine and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.; Institute of Genetics, Zhejiang University and Department of Genetics, Zhejiang University School of Medicine, Hangzhou, 310058, China.; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, 311121, China.
Fang H; Institute of Genetics, Zhejiang University and Department of Genetics, Zhejiang University School of Medicine, Hangzhou, 310058, China.
Zhang J; Division of Genome Medicine and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. .
Gu Y; Division of Genome Medicine and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China. .; Institute of Genetics, Zhejiang University and Department of Genetics, Zhejiang University School of Medicine, Hangzhou, 310058, China. .; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, 311121, China. .
Pokaż więcej
Źródło :
Frontiers of medicine [Front Med] 2021 Aug; Vol. 15 (4), pp. 541-550. Date of Electronic Publication: 2021 Mar 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Neoplasms*/drug therapy
Neoplasms*/genetics
Synthetic Lethal Mutations*
Humans ; Mutation ; Proteins ; Proto-Oncogene Proteins c-myc/genetics
Czasopismo naukowe
Tytuł :
KG4SL: knowledge graph neural network for synthetic lethality prediction in human cancers.
Autorzy :
Wang S; School of Information Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Xu F; School of Information Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Li Y; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Wang J; School of Information Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Zhang K; School of Information Science and Technology, ShanghaiTech University, Shanghai 201210, China.; Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai 200050, China.
Liu Y; Joint NTU-UBC Research Centre of Excellence in Active Living for the Elderly, Nanyang Technological University, Singapore 639798, Singapore.
Wu M; Institute for Infocomm Research, Agency for Science, Technology and Research (A*STAR), Singapore 138632, Singapore.
Zheng J; School of Information Science and Technology, ShanghaiTech University, Shanghai 201210, China.; Shanghai Engineering Research Center of Intelligent Vision and Imaging, Shanghai, 201210, China.
Pokaż więcej
Źródło :
Bioinformatics (Oxford, England) [Bioinformatics] 2021 Jul 12; Vol. 37 (Suppl_1), pp. i418-i425.
Typ publikacji :
Journal Article
MeSH Terms :
Neoplasms*/genetics
Synthetic Lethal Mutations*
Humans ; Neural Networks, Computer ; Pattern Recognition, Automated ; Proteomics
Czasopismo naukowe
Tytuł :
SynLeGG: analysis and visualization of multiomics data for discovery of cancer 'Achilles Heels' and gene function relationships.
Autorzy :
Wappett M; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT9 7AE, UK.; Drug Discovery, Almac Discovery Ltd, Belfast BT9 7AE, UK.
Harris A; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT9 7AE, UK.
Lubbock ALR; Department of Biochemistry, Vanderbilt University, Nashville, TN 37232, USA.
Lobb I; Drug Discovery, Almac Discovery Ltd, Belfast BT9 7AE, UK.
McDade S; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT9 7AE, UK.
Overton IM; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT9 7AE, UK.
Pokaż więcej
Źródło :
Nucleic acids research [Nucleic Acids Res] 2021 Jul 02; Vol. 49 (W1), pp. W613-W618.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Genes, Neoplasm*
Software*
Synthetic Lethal Mutations*
Neoplasms/*genetics
CRISPR-Cas Systems ; Cell Line, Tumor ; Gene Expression ; Gene Expression Profiling ; Humans ; Mutation ; Proteomics
Czasopismo naukowe
Tytuł :
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Autorzy :
Zatreanu D; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Robinson HMR; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Alkhatib O; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Boursier M; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Finch H; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Geo L; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Grande D; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Grinkevich V; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Heald RA; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Langdon S; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Majithiya J; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
McWhirter C; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Martin NMB; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Moore S; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Neves J; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Rajendra E; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Ranzani M; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Schaedler T; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Stockley M; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Wiggins K; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.
Brough R; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Sridhar S; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Gulati A; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Shao N; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Badder LM; The Breast Cancer Now Research Unit, King's College London, London, UK.
Novo D; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Knight EG; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Marlow R; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Research Unit, King's College London, London, UK.
Haider S; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Callen E; Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Hewitt G; The Francis Crick Institute, London, UK.
Schimmel J; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Prevo R; Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, UK.
Alli C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Ferdinand A; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Bell C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Blencowe P; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Bot C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Calder M; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Charles M; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Curry J; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Ekwuru T; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Ewings K; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Krajewski W; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
MacDonald E; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
McCarron H; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Pang L; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Pedder C; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Rigoreau L; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Swarbrick M; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Wheatley E; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Willis S; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Wong AC; Cancer Research UK, Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK.
Nussenzweig A; Laboratory of Genome Integrity, National Cancer Institute, NIH, Bethesda, MD, USA.
Tijsterman M; Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Tutt A; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.; The Breast Cancer Now Research Unit, King's College London, London, UK.
Boulton SJ; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK.; The Francis Crick Institute, London, UK.
Higgins GS; Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, UK.
Pettitt SJ; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK. .; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. .
Smith GCM; Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK. .
Lord CJ; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK. .; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Jun 17; Vol. 12 (1), pp. 3636. Date of Electronic Publication: 2021 Jun 17.
Typ publikacji :
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
MeSH Terms :
BRCA1 Protein/*genetics
BRCA2 Protein/*genetics
DNA Repair/*drug effects
DNA-Directed DNA Polymerase/*genetics
Nucleic Acid Synthesis Inhibitors/*pharmacology
Poly(ADP-ribose) Polymerase Inhibitors/*pharmacology
Synthetic Lethal Mutations/*drug effects
Allosteric Regulation ; Animals ; Apoptosis/drug effects ; Apoptosis/genetics ; BRCA1 Protein/metabolism ; BRCA2 Protein/metabolism ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Proliferation/genetics ; Cell Survival/drug effects ; Cell Survival/radiation effects ; DNA Damage/drug effects ; DNA-Binding Proteins/metabolism ; DNA-Directed DNA Polymerase/metabolism ; Deoxyribonucleases/antagonists & inhibitors ; Drug Resistance, Neoplasm ; Drug Screening Assays, Antitumor ; Female ; Homologous Recombination/drug effects ; Humans ; Inhibitory Concentration 50 ; Mice ; Organoids/drug effects ; Ovarian Neoplasms/genetics ; Rats ; Synthetic Lethal Mutations/genetics ; Tumor Suppressor p53-Binding Protein 1/deficiency ; Tumor Suppressor p53-Binding Protein 1/metabolism
Czasopismo naukowe
Tytuł :
FANCM regulates repair pathway choice at stalled replication forks.
Autorzy :
Panday A; Department of Medicine, Division of Hematology-Oncology and Cancer Research Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA.
Willis NA; Department of Medicine, Division of Hematology-Oncology and Cancer Research Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA.
Elango R; Department of Medicine, Division of Hematology-Oncology and Cancer Research Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA.
Menghi F; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06030, USA.
Duffey EE; Department of Medicine, Division of Hematology-Oncology and Cancer Research Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA.
Liu ET; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06030, USA.
Scully R; Department of Medicine, Division of Hematology-Oncology and Cancer Research Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA. Electronic address: .
Pokaż więcej
Źródło :
Molecular cell [Mol Cell] 2021 Jun 03; Vol. 81 (11), pp. 2428-2444.e6. Date of Electronic Publication: 2021 Apr 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA Repair*
DNA Replication*
Synthetic Lethal Mutations*
BRCA1 Protein/*genetics
DNA Helicases/*genetics
Mouse Embryonic Stem Cells/*metabolism
Animals ; BRCA1 Protein/metabolism ; Cell Cycle/genetics ; Cell Line ; Clone Cells ; DNA Helicases/metabolism ; Fanconi Anemia Complementation Group D2 Protein/genetics ; Fanconi Anemia Complementation Group D2 Protein/metabolism ; Fibroblasts/cytology ; Fibroblasts/metabolism ; Humans ; Mice ; Mouse Embryonic Stem Cells/cytology ; Ubiquitination
Czasopismo naukowe
Tytuł :
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Autorzy :
Chabanon RM; ATIP-Avenir group, Inserm Unit U981, Gustave Roussy, Villejuif, France.; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Morel D; ATIP-Avenir group, Inserm Unit U981, Gustave Roussy, Villejuif, France.; Université Paris Saclay, Université Paris-Sud, Faculté de Médicine, Le Kremlin Bicêtre, France.
Eychenne T; ATIP-Avenir group, Inserm Unit U981, Gustave Roussy, Villejuif, France.
Colmet-Daage L; ATIP-Avenir group, Inserm Unit U981, Gustave Roussy, Villejuif, France.
Bajrami I; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Dorvault N; ATIP-Avenir group, Inserm Unit U981, Gustave Roussy, Villejuif, France.
Garrido M; ATIP-Avenir group, Inserm Unit U981, Gustave Roussy, Villejuif, France.
Meisenberg C; Epigenetics and Genome Stability Team, The Institute of Cancer Research, London, United Kingdom.
Lamb A; Sage Bionetworks, Seattle, Washington.
Ngo C; ATIP-Avenir group, Inserm Unit U981, Gustave Roussy, Villejuif, France.
Hopkins SR; Epigenetics and Genome Stability Team, The Institute of Cancer Research, London, United Kingdom.
Roumeliotis TI; Functional Proteomics Team, The Institute of Cancer Research, London, United Kingdom.
Jouny S; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Hénon C; ATIP-Avenir group, Inserm Unit U981, Gustave Roussy, Villejuif, France.
Kawai-Kawachi A; ATIP-Avenir group, Inserm Unit U981, Gustave Roussy, Villejuif, France.
Astier C; ATIP-Avenir group, Inserm Unit U981, Gustave Roussy, Villejuif, France.
Konde A; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Del Nery E; Institut Curie, PSL Research University, Department of Translational Research, The Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France.
Massard C; Drug Development Department, DITEP, Gustave Roussy, Villejuif, France.
Pettitt SJ; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
Margueron R; Institut Curie, PSL Research University, INSERM Unit U934, CNRS UMR 3215, Paris, France.
Choudhary JS; Functional Proteomics Team, The Institute of Cancer Research, London, United Kingdom.
Almouzni G; Institut Curie, PSL Research University, CNRS, UMR 3664, Equipe Labellisée Ligue contre le Cancer, Paris, France.; Sorbonne Universités, UPMC Université Paris-VI, CNRS, UMR3664, Paris, France.
Soria JC; Université Paris Saclay, Université Paris-Sud, Faculté de Médicine, Le Kremlin Bicêtre, France.
Deutsch E; Université Paris Saclay, Université Paris-Sud, Faculté de Médicine, Le Kremlin Bicêtre, France.; INSERM UMR1030 Molecular Radiotherapy and Therapeutic Innovations, Gustave Roussy, Villejuif, France.
Downs JA; Epigenetics and Genome Stability Team, The Institute of Cancer Research, London, United Kingdom.
Lord CJ; The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. .
Postel-Vinay S; ATIP-Avenir group, Inserm Unit U981, Gustave Roussy, Villejuif, France. .; Université Paris Saclay, Université Paris-Sud, Faculté de Médicine, Le Kremlin Bicêtre, France.; Drug Development Department, DITEP, Gustave Roussy, Villejuif, France.
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2021 Jun 01; Vol. 81 (11), pp. 2888-2902.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA Repair*
Synthetic Lethal Mutations*
DNA-Binding Proteins/*deficiency
Gene Expression Regulation, Neoplastic/*drug effects
Kidney Neoplasms/*pathology
Lung Neoplasms/*pathology
Poly(ADP-ribose) Polymerase Inhibitors/*pharmacology
Transcription Factors/*deficiency
Animals ; Apoptosis ; Ataxia Telangiectasia Mutated Proteins/antagonists & inhibitors ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/genetics ; Carcinoma, Renal Cell/metabolism ; Carcinoma, Renal Cell/pathology ; Cell Proliferation ; Female ; Humans ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/genetics ; Kidney Neoplasms/metabolism ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
CCNE1 Is a Putative Therapeutic Target for ARID1A -Mutated Ovarian Clear Cell Carcinoma.
Autorzy :
Kawahara N; Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8521, Japan.
Yamada Y; Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8521, Japan.
Kobayashi H; Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8521, Japan.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 May 30; Vol. 22 (11). Date of Electronic Publication: 2021 May 30.
Typ publikacji :
Journal Article
MeSH Terms :
Synthetic Lethal Mutations*
Adenocarcinoma, Clear Cell/*genetics
Cyclin E/*genetics
DNA-Binding Proteins/*genetics
Oncogene Proteins/*genetics
Ovarian Neoplasms/*genetics
Transcription Factors/*genetics
Adenocarcinoma, Clear Cell/metabolism ; Adenocarcinoma, Clear Cell/pathology ; Animals ; Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; Apoptosis/genetics ; Cell Cycle/drug effects ; Cell Cycle/genetics ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cisplatin/pharmacology ; Cyclin E/antagonists & inhibitors ; Cyclin E/metabolism ; DNA-Binding Proteins/antagonists & inhibitors ; DNA-Binding Proteins/metabolism ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Mice ; Mice, Nude ; Molecular Targeted Therapy ; Oncogene Proteins/antagonists & inhibitors ; Oncogene Proteins/metabolism ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism ; Transcription Factors/antagonists & inhibitors ; Transcription Factors/metabolism ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Breast Cancer Predisposition Genes and Synthetic Lethality.
Autorzy :
Neiger HE; College of Graduate Studies, California Northstate University, Elk Grove, CA 95757, USA.
Siegler EL; College of Medicine, California Northstate University, Elk Grove, CA 95757, USA.
Shi Y; College of Medicine, California Northstate University, Elk Grove, CA 95757, USA.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 May 25; Vol. 22 (11). Date of Electronic Publication: 2021 May 25.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Genetic Predisposition to Disease*
Synthetic Lethal Mutations*
BRCA1 Protein/*genetics
BRCA2 Protein/*genetics
Breast Neoplasms/*genetics
Fanconi Anemia Complementation Group N Protein/*genetics
Breast Neoplasms/therapy ; DNA Repair ; Female ; Humans
Czasopismo naukowe
Tytuł :
Setting molecular traps in yeast for identification of anticancer drug targets.
Autorzy :
Brown GW; The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada; .; Department of Biochemistry, University of Toronto, Toronto, ON M5S 1A8, Canada.
Andrews B; The Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada; .; Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2021 May 04; Vol. 118 (18).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
DNA-Binding Proteins/*genetics
Flap Endonucleases/*genetics
Neoplasms/*drug therapy
Small Molecule Libraries/*pharmacology
Synthetic Lethal Mutations/*genetics
Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; DNA Repair/drug effects ; DNA-Binding Proteins/chemistry ; Drug Delivery Systems ; Flap Endonucleases/antagonists & inhibitors ; Homologous Recombination/drug effects ; Humans ; Multiprotein Complexes/genetics ; Neoplasms/genetics ; Parthanatos/drug effects ; Poly (ADP-Ribose) Polymerase-1/genetics ; Saccharomyces cerevisiae/genetics ; Small Molecule Libraries/chemistry ; Synthetic Lethal Mutations/drug effects
Czasopismo naukowe
Tytuł :
Modeling DNA trapping of anticancer therapeutic targets using missense mutations identifies dominant synthetic lethal interactions.
Autorzy :
Hamza A; Michael Smith Laboratories, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Amitzi L; Michael Smith Laboratories, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Ma L; Michael Smith Laboratories, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Driessen MRM; Michael Smith Laboratories, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
O'Neil NJ; Michael Smith Laboratories, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Hieter P; Michael Smith Laboratories, University of British Columbia, Vancouver, BC V6T 1Z4, Canada .
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2021 Apr 06; Vol. 118 (14).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Mutation, Missense*
Synthetic Lethal Mutations*
DNA/*metabolism
Flap Endonucleases/*metabolism
Antineoplastic Agents/toxicity ; Chromosomal Proteins, Non-Histone/genetics ; Chromosomal Proteins, Non-Histone/metabolism ; DNA/chemistry ; Drug Development/methods ; Flap Endonucleases/genetics ; Genetic Techniques ; Humans ; Protein Binding ; Saccharomyces cerevisiae ; Saccharomyces cerevisiae Proteins/genetics ; Saccharomyces cerevisiae Proteins/metabolism
Czasopismo naukowe
Tytuł :
Synthetic lethality-mediated precision oncology via the tumor transcriptome.
Autorzy :
Lee JS; Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Next Generation Medicine Lab, Department of Artificial Intelligence & Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon 16419, Republic of Korea; Department of Digital Health & Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Samsung Medical Center, Sungkyunkwan University, Seoul 06351, Republic of Korea. Electronic address: .
Nair NU; Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Dinstag G; Pangea Therapeutics, Ltd., Tel Aviv 6971003, Israel.
Chapman L; Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Chung Y; Next Generation Medicine Lab, Department of Artificial Intelligence & Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Wang K; Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Sinha S; Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cha H; Department of Digital Health & Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Samsung Medical Center, Sungkyunkwan University, Seoul 06351, Republic of Korea.
Kim D; Next Generation Medicine Lab, Department of Artificial Intelligence & Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Schperberg AV; Department of Mechanical and Aerospace Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Srinivasan A; Research and Innovations Group, Datar Cancer Genetics Limited, Nasik, Maharashtra 422010, India.
Lazar V; Worldwide Innovative Network (WIN) Association-WIN Consortium, Villejuif 94801, France.
Rubin E; The Center for Evolutionary Genomics and Medicine, Ben-Gurion University of the Negev, Beersheva 8410501, Israel.
Hwang S; Department of Pathology, CHA University, CHA Bundang Medical Center, Seongnam 13497, Republic of Korea.
Berger R; Cancer Center, Chaim Sheba Medical Center, Tel Hashomer 5262000, Israel.
Beker T; Pangea Therapeutics, Ltd., Tel Aviv 6971003, Israel.
Ronai Z; Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Hannenhalli S; Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Gilbert MR; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Kurzrock R; Worldwide Innovative Network (WIN) Association-WIN Consortium, Villejuif 94801, France; Moore Cancer Center, University of California, San Diego, San Diego, CA 92037, USA.
Lee SH; Department of Digital Health & Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Samsung Medical Center, Sungkyunkwan University, Seoul 06351, Republic of Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea.
Aldape K; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Ruppin E; Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: .
Pokaż więcej
Źródło :
Cell [Cell] 2021 Apr 29; Vol. 184 (9), pp. 2487-2502.e13. Date of Electronic Publication: 2021 Apr 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Molecular Targeted Therapy*
Precision Medicine*
Synthetic Lethal Mutations*
Biomarkers, Tumor/*genetics
Gene Expression Regulation, Neoplastic/*drug effects
Neoplasms/*drug therapy
Transcriptome/*drug effects
Aged ; Biomarkers, Tumor/antagonists & inhibitors ; Biomarkers, Tumor/immunology ; Clinical Trials as Topic ; Female ; Follow-Up Studies ; Humans ; Immunotherapy ; Male ; Neoplasms/genetics ; Neoplasms/pathology ; Prognosis ; Prospective Studies ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
Autorzy :
Patel PS; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Algouneh A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Hakem R; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. .; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. .; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. .
Pokaż więcej
Źródło :
Oncogene [Oncogene] 2021 Apr; Vol. 40 (17), pp. 3001-3014. Date of Electronic Publication: 2021 Mar 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
BRCA1 Protein*
BRCA2 Protein*
Synthetic Lethal Mutations*
Humans
Czasopismo naukowe
Tytuł :
The haplolethality paradox of the wupA gene in Drosophila.
Autorzy :
Casas-Tintó S; Instituto Cajal, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
Ferrús A; Instituto Cajal, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
Pokaż więcej
Źródło :
PLoS genetics [PLoS Genet] 2021 Mar 19; Vol. 17 (3), pp. e1009108. Date of Electronic Publication: 2021 Mar 19 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Haplotypes*
Synthetic Lethal Mutations*
Drosophila/*genetics
Drosophila Proteins/*genetics
Troponin I/*genetics
Animals ; Chromosome Duplication ; Chromosome Mapping ; Female ; Gene Expression Regulation ; Genetic Association Studies ; Male ; Phenotype
Czasopismo naukowe
Tytuł :
Leveraging microenvironmental synthetic lethalities to treat cancer.
Autorzy :
Metcalf KJ; Department of Surgery.; Department of Anatomy.
Alazzeh A; Department of Anatomy.
Werb Z; Department of Anatomy.; Helen Diller Family Comprehensive Cancer Center.
Weaver VM; Department of Surgery.; Helen Diller Family Comprehensive Cancer Center.; Center for Bioengineering and Tissue Regeneration, and.; Radiation Oncology, Department of Bioengineering and Therapeutic Sciences, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California, San Francisco, California, USA.
Pokaż więcej
Źródło :
The Journal of clinical investigation [J Clin Invest] 2021 Mar 15; Vol. 131 (6).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Synthetic Lethal Mutations*
Neoplasms/*genetics
Neoplasms/*therapy
Tumor Microenvironment/*genetics
Animals ; Disease Progression ; Drug Resistance, Neoplasm/genetics ; Female ; Humans ; Immunotherapy ; Male ; Molecular Targeted Therapy ; Neoplasms/immunology ; Signal Transduction/genetics
Czasopismo naukowe
Tytuł :
Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age.
Autorzy :
Thng DKH; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Toh TB; The N.1 Institute for Health, National University of Singapore, Singapore; The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Chow EK; Cancer Science Institute of Singapore, National University of Singapore, Singapore; The N.1 Institute for Health, National University of Singapore, Singapore; The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Biomedical Engineering, National University of Singapore, Singapore. Electronic address: .
Pokaż więcej
Źródło :
Trends in pharmacological sciences [Trends Pharmacol Sci] 2021 Mar; Vol. 42 (3), pp. 166-182. Date of Electronic Publication: 2021 Jan 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Neoplasms*/drug therapy
Neoplasms*/genetics
Proto-Oncogene Proteins c-myc*/genetics
Synthetic Lethal Mutations*
Humans ; Oncogenes
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies